Ruxo,Tofa both score >90 on SALT after 180 days | CNCE Message Board Posts

Concert Pharmaceuticals, Inc.

  CNCE website

CNCE   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  1298 of 1460  at  12/26/2018 6:56:17 PM  by

thecroup


 In response to msg 1297 by  biobetter
view thread

Re: Ruxo,Tofa both score >90 on SALT after 180 days

Tofacitinib has a "box warning" and is dose limited to 5mg bid, which is why Pfizer set out to find another safer drug for Alopecia Areata. The drug that they settled on is PF-06651600. Head to head comparison's of their new drug to CTP-543, have already been dissected many times over, since they both completed phase 2 clinical trials. 
It's good to see Ruxolitinib's safety profile in the study posted, which gives me more confidence that CTP-543 12mg bid, may be well-tolerated also. CTP-543 could be comparable to Ruxolitinib to around 14.4mg, as it was shown to have approximately 20% increase in phase 1 clinical trials. 


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 4     Views: 147
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board


About Us    Contact Us    Follow Us on Twitter    Members Directory    Help Center    Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
2003-2018 Investorvillage.com. All rights reserved. User Agreement
   
Financial Market Data provided by
.


Loading...